We are live on
!
Find out more
FO
FT Options Portfolio holdings
AUM
$66.4M
1-Year Est. Return
18.48%
This Fund
S&P 500
This Quarter
Est. Return
-15.35%
1 Year Est. Return
+18.48%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$95.5M
AUM Growth
-$40.1M
(-30%)
Cap. Flow
+$254M
Cap. Flow
% of AUM
266.32%
Top 10 Holdings %
Top 10 Hldgs %
44.8%
Holding
389
New
183
Increased
50
Reduced
47
Closed
99
Top Buys
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$10.6M |
| 2 |
Baxter International
BAX
|
+$3.81M |
| 3 |
Akebia Therapeutics
AKBA
|
+$2.87M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$2.46M |
| 5 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$1.81M |
Top Sells
| 1 |
Gilead Sciences
GILD
|
+$8.82M |
| 2 |
CELG
Celgene Corp
CELG
|
+$6.57M |
| 3 |
DYAX
DYAX CORPORATION
DYAX
|
+$6.35M |
| 4 |
Chipotle Mexican Grill
CMG
|
+$5.44M |
| 5 |
Viatris
VTRS
|
+$2.57M |
Sector Composition
| 1 | Healthcare | 48.43% |
| 2 | Technology | 4.06% |
| 3 | Consumer Discretionary | 2.5% |
| 4 | Consumer Staples | 1.74% |
| 5 | Materials | 1.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Arrowhead Research
ARWR
$10.1B
| $384K | 0.4% |
79,705
+27,858
| +54% | +$117K |
|
52
PUT
MannKind Corp
MNKD
$1.25B
| $382K | 0.4% |
59,180
+9,180
| +18% | +$52.5K |
|
|
LUMO
53
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $382K | 0.4% |
2,334
-2,879
| -55% | -$584K |
|
|
ICPT
54
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $350K | 0.37% |
35,500
+2,300
| +7% | +$272K |
|
55
CALL
AT&T
T
$153B
| $348K | 0.36% |
278,305
+24,759
| +10% | +$686K |
|
|
THS
56
DELISTED
Treehouse Foods
THS
| $342K | 0.36% |
+3,937
| New | +$315K |
|
|
ANAC
57
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $342K | 0.36% |
56,100
+46,100
| +461% | +$3.4M |
|
58
CALL
Molson Coors Class B
TAP
$7.84B
| $335K | 0.35% |
29,100
-49,100
| -63% | -$4.38M |
|
59
Macy's
M
$6.34B
| $331K | 0.35% |
+7,500
| New | +$310K |
|
60
CALL
Biogen
BIIB
$30.8B
| $306K | 0.32% |
32,200
+14,900
| +86% | +$3.94M |
|
61
CALL
General Mills
GIS
$20.7B
| $304K | 0.32% |
+134,800
| New | +$7.83M |
|
62
Accenture
ACN
$88.5B
| $300K | 0.31% |
+2,600
| New | +$267K |
|
63
CALL
Kimberly-Clark
KMB
$36.2B
| $300K | 0.31% |
+96,800
| New | +$12.6M |
|
64
Radware
RDWR
$1.27B
| $296K | 0.31% |
+25,000
| New | +$302K |
|
|
65
Biogen
BIIB
$30.8B
| $291K | 0.3% |
1,116
-4,100
| -79% | -$1.08M |
|
66
CALL
Norfolk Southern
NSC
$75.9B
| $288K | 0.3% |
+71,800
| New | +$5.43M |
|
|
RLYP
67
CALL
DELISTED
RELYPSA INC COM
RLYP
| $286K | 0.3% |
175,100
+63,500
| +57% | +$1.08M |
|
68
CALL
RTX Corp
RTX
$262B
| $277K | 0.29% |
+105,033
| New | +$6.09M |
|
69
CALL
Verizon
VZ
$183B
| $262K | 0.27% |
57,500
-2,500
| -4% | -$125K |
|
70
PUT
Cal-Maine
CALM
$4.18B
| $257K | 0.27% |
143,100
+99,500
| +228% | +$4.97M |
|
|
GWPH
71
PUT
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $254K | 0.27% |
29,900
-21,400
| -42% | -$1.17M |
|
72
PUT
Alibaba
BABA
$282B
| $252K | 0.26% |
11,100
| – | – |
|
73
CALL
Intuitive Surgical
ISRG
$142B
| $232K | 0.24% |
+90,000
| New | +$5.58M |
|
74
The Mosaic Company
MOS
$7.16B
| $232K | 0.24% |
+8,600
| New | +$224K |
|
|
ACHN
75
DELISTED
Achillion Pharmaceuticals
ACHN
| $232K | 0.24% |
+30,000
| New | +$220K |
|
Similar funds
MC
FIM
TLIC
MKCM
ACM
MFM
VE
GFWEV
FT Options's Q1 2016 Portfolio in Review
As of Q1 2016, FT Options held 389 positions worth $95.5M, down 30% from $136M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
FT Options deployed $254M of net new capital in Q1 2016, opening 183 new positions and adding to 50 existing holdings. Its largest new stake was Baxter International: 100,000 shares worth $4.11M.
By sector, the portfolio is most concentrated in Healthcare at 48% of assets, up from 43% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Gilead Sciences, an estimated $8.82M trimmed.
- FT Options's largest Q1 2016 buy was Baxter International: 100,000 shares worth $4.11M.
- FT Options added most to Regeneron Pharmaceuticals in Q1 2016, an estimated $10.6M increase.
- FT Options's biggest Q1 2016 reduction was Gilead Sciences, cutting an estimated $8.82M.
- FT Options fully exited Celgene Corp in Q1 2016, selling an estimated $6.57M.
- FT Options's ten largest holdings make up 45% of its $95.5M portfolio in Q1 2016.
- FT Options opened 183 new positions and closed 99 in Q1 2016.
- FT Options's portfolio value fell 30% quarter-over-quarter to $95.5M.
Based on FT Options's 13F filing for Q1 2016, filed 9 May 2016.